Brightspring Health Services Inc

Brightspring Health Services Inc(BTSG)の株式分析

$62.360

-0.062 (-0.10%)終値時点

Loading chart…
高値
63.430
始値
63.005
出来高加重平均価格
62.73
出来高
1.64M
時価総額
—
安値
62.402
売買代金
102.90M
EV/EBITDA(TTM)
18.97

BrightSpring Health Services, Inc. provides complementary home and community-based pharmacy and provides health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care and rehab care, it provides comprehensive and more integrated care and clinical solutions in all 50 states to customers, clients and patients. Its services are organized and managed through two reportable segments: Pharmacy Solutions and Provider Services. The Pharmacy Solutions segment operates long-term institutional pharmacies, hospice pharmacies, specialty oncology pharmacies, and home infusion centers. It provides infused, injectable, and oral medication services in the home and clinic. The Provider Services segment provides a variety of services to help manage the whole-person health of its patients in their homes and communities through services such as home health care and hospice care and long-term specialty care.

AI分析 of Brightspring Health Services Inc (BTSG)

中立

Brightspring Health Services Inc (BTSG) is currently priced at $60.87, which is below several analyst price targets, including $70 from Deutsche Bank and $80 from KeyBanc. However, the stock has a low RSI of 39.53, indicating potential oversold conditions, but it also experienced a significant 4.5% drop over the last five days. The company has shown strong revenue growth, with a 58.52% year-to-date increase, but concerns about its free cash flow margin averaging only 1.3% could limit its ability to return capital to shareholders. Given these factors, it may be prudent to hold rather than buy at this time, especially considering the recent volatility in the stock price.

バリュエーション指標

Brightspring Health Services Inc(BTSG)の現在の予想PERは22.17で、5年平均は27.10です。

予想PER

適正
5年平均 P/E
27.10
現在のP/E
22.17
割高
35.41
割安
18.79

予想EV/EBITDA

割高
5年平均 EV/EBITDA
12.93
現在のEV/EBITDA
18.97
割高
17.03
割安
8.83

予想PSR

割高
5年平均 P/S
0.38
現在のP/S
0.71
割高
0.57
割安
0.19

Alphio AI による BTSG の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%BTSG

$28.42

シナリオ価格

基

基本

基本 · 50%BTSG

$25.10

シナリオ価格

弱

弱気

弱気 · 25%BTSG

$20.54

シナリオ価格

BTSG を保有するクジラ

B

Braidwell LP

+ を保有BTSG

+22.04%

3か月リターン

O

Oak Ridge Investments, LLC

+ を保有BTSG

+10.16%

3か月リターン

C

CastleArk Management LLC

+ を保有BTSG

+8.92%

3か月リターン

F

Farallon Capital Management, L.L.C.

+ を保有BTSG

+3.59%

3か月リターン

B

Blackstone Alternative Investment Advisors LLC

+ を保有BTSG

+1.19%

3か月リターン

K

KKR & Co. Inc.

+ を保有BTSG

-1.55%

3か月リターン

BTSG のよくある質問 — Alphio AI が回答

BrightSpring Health Services, Inc. provides complementary home and community-based pharmacy and provides health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care and rehab care, it provides comprehensive and more integrated care and clinical solutions in all 50 states to customers, clients and patients. Its services are organized and managed through two reportable segments: Pharmacy Solutions and Provider Services. The Pharmacy Solutions segment operates long-term institutional pharmacies, hospice pharmacies, specialty oncology pharmacies, and home infusion centers. It provides infused, injectable, and oral medication services in the home and clinic. The Provider Services segment provides a variety of services to help manage the whole-person health of its patients in their homes and communities through services such as home health care and hospice care and long-term specialty care. It operates in the Healthcare sector (HOME HEALTH CARE SERVICES industry).

Brightspring Health Services Inc (BTSG) is currently priced at $60.87, which is below several analyst price targets, including $70 from Deutsche Bank and $80 from KeyBanc. However, the stock has a low RSI of 39.53, indicating potential oversold conditions, but it also experienced a significant 4.5% drop over the last five days. The company has shown strong revenue growth, with a 58.52% year-to-date increase, but concerns about its free cash flow margin averaging only 1.3% could limit its ability to return capital to shareholders. Given these factors, it may be prudent to hold rather than buy at this time, especially considering the recent volatility in the stock price.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める